Incorporated in January 1999, Sai Life Sciences Limited researches, develops, and manufactures small-molecule new chemical entities. The company offers tailor-made services to biotech firms and global pharma companies.
In the Financial Year 2024 and for the month ending September 30, 2024, the company provided services to over 280 innovator pharmaceutical companies, including more than 230 in that month alone. Among these clients, the company worked with 18 of the top 25 pharmaceutical companies based on their revenue in the calendar year 2023.The services were offered across countries such as the US, the UK, Europe, and Japan.
The company's business development team consists of 16 experienced and qualified professionals, with six located in the US, nine in the UK and Europe, and one in Japan.
The company has the following service offerings.
- Capabilities in chemistry, manufacturing, and control(“CMC”)/contract development and manufacturing organisations (“CDMO”).
- CRO services include integrated discovery (“Discovery”) capabilities across biology, chemistry, drug metabolism and pharmacokinetics
As of September 30, 2024, the company had 2,353 scientific staff, with the majority of the scientific team holding advanced degrees, including 302 Ph. D.s and 1,475 master’s degrees.
As of September 30, 2024, the company had 3135 employees with capabilities across the CRDMO value chain.
Competitive Strength:
- As an integrated CRDMO, the company provide a complete platform for discovery, development, and manufacturing.
- CRO services include integrated discovery capabilities across biology, chemistry, and drug metabolism and pharmacokinetics.
- CDMO platform with a diverse mix of commercial and under-development molecules
| Purpose | Amount (₹ Cr) |
|---|---|
| Repayment/prepayment in full or part, of all or certain outstanding borrowings availed by the Company and | — |
| General corporate purposes | — |
| Metric | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Total Assets | 2,477 | 2,275 | 2,187 |
| Revenue | 693 | 1,494 | 1,245 |
| PAT | 28 | 83 | 10 |
| Net Worth | 1,045 | 974 | 887 |
| Reserves | 1,025 | 954 | 867 |
| Total Borrowing | 764 | 710 | 699 |
| Category | Sub (x) | Offered | Bid For |
|---|---|---|---|
| QIB | — | 27,710,560 (50%) | — |
| NII / HNI | — | 8,313,169 (15%) | — |
| Retail (RII) | — | 19,397,394 (35%) | — |
| Total | — | 55,421,123 (100%) | — |
* Amount calculated at upper price band (₹549) · ** Total includes all investor categories
- 1 Initiation of Refund 17 Dec 2024
- 2 Credit of Shares to Demat 17 Dec 2024
- 3 Lock-in Period (30%) January 14, 2025
- 4 Lock-in Period (50%) March 15, 2025
- Retail allocation is good at 35% of the total offering.
- HNI/NII demand is good at 15%.
- Institutional (QIB) interest is strong at 50%.
- The IPO P/E of 204x reflects a weak valuation relative to typical market ranges.
- Pre-issue EPS of ₹4 compares to post-issue EPS of ₹3 after dilution.
This IPO shows moderate investor interest. Review financial details and compare valuation with industry peers before investing.
The information on mainboardgmp.com is provided for educational and informational purposes only.
We are not a Securities and Exchange Board of India (SEBI)-registered investment advisor, analyst, broker, or financial planner. The content, data, and insights on this website, including Grey Market Premium (GMP), subscription data, IPO dates, and market information, are not intended as financial advice or recommendations to buy, sell, or hold securities.
GMP and related IPO data are collected from unofficial market sources and may not reflect actual IPO listing performance or future price movements. You should not rely solely on the information provided here to make financial or investment decisions.
Investing in IPOs and securities involves risk. Always conduct your own research and consult a qualified SEBI-registered financial advisor before making investment decisions. mainboardgmp.com and its owners shall not be liable for any financial losses, trading losses, or damages arising from use of this website.
By accessing and using mainboardgmp.com, you agree to be bound by these Terms & Conditions. If you do not agree with any part of these terms, you should not use this website.
mainboardgmp.com provides information related to IPOs, including Grey Market Premium (GMP), subscription status, IPO dates, company details, and market trends. All content is for informational purposes only.
Nothing on this website constitutes financial, investment, tax, or legal advice. The content does not constitute a recommendation to invest in any securities, and no assurance is made regarding the accuracy, completeness, or reliability of any information. You should independently verify all information and consult qualified professionals before making investment decisions.
We strive to provide accurate and up-to-date information, but we do not guarantee that all content is correct, complete, or current at all times. IPO details and GMP data are subject to change without notice.
All content, design, graphics, and data on this website belong to mainboardgmp.com and may not be copied, reproduced, or redistributed without express written permission.
You agree not to use the website for unlawful purposes or in a way that may harm, disable, or impair the site's operation.
To the maximum extent permitted by law, mainboardgmp.com and its affiliates shall not be liable for any losses, damages, costs, or expenses arising out of your use of this website.
These Terms shall be governed by the laws of India. Any disputes will be subject to the exclusive jurisdiction of courts located in Kolkata, West Bengal.
We reserve the right to modify these Terms at any time. Continued use of the site constitutes acceptance of the updated Terms.
We may collect: email address (if submitted voluntarily), IP address, browser and device information, cookies and usage data. We do not collect sensitive personal information unless voluntarily provided.
Collected data may be used to improve website performance, respond to inquiries, send newsletters or updates (if you subscribe), and analyze traffic through analytics tools.
We use cookies and similar technologies to enhance user experience and track website usage. Users can disable cookies through browser settings.
We may use third-party services (e.g., Google Analytics) that collect demographic and usage data to help us understand traffic and improve services.
We do not sell personal information. We may share data with service providers (e.g., analytics providers) who assist with website operations.
Reasonable measures are taken to protect user data, but no online transmission can be guaranteed 100% secure.
This website is not directed at children under the age of 18.
We may update this Privacy Policy at any time. Continued use of the website constitutes acceptance of changes.
For privacy concerns, please contact us via the Support page.